Journal
STEM CELLS AND DEVELOPMENT
Volume 22, Issue 1, Pages 27-30Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/scd.2012.0404
Keywords
-
Funding
- [R21 HD060978]
Ask authors/readers for more resources
Infusion of autologous bone marrow-derived mononuclear cells (MNCs) is a promising investigational therapeutic approach for patients with acute ischemic stroke. Preclinical models indicate that MNCs can reduce neurological deficits and enhance recovery. We recently concluded a phase I clinical trial to determine the safety and feasibility of these cells in patients with acute ischemic stroke. In this article, we discuss practical barriers and challenges encountered during the trial and provide lessons learned for the design and planning of future clinical trials testing novel cell therapies for acute ischemic stroke.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available